Drug Type Small molecule drug |
Synonyms GST-HG171/Ritonavir, 泰阿特韦/利托那韦, Tazovid + [1] |
Mechanism HIV-1 protease inhibitors(HIV protease inhibitors), SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (23 Nov 2023), |
RegulationConditional marketing approval (CN), Special Review Project (CN) |
Molecular FormulaC24H32F3N5O4 |
InChIKeyGTRJFXDJASEGSW-KBCNZALWSA-N |
CAS Registry2850365-55-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | CN | 23 Nov 2023 |
Corporate Publications Manual | Phase 2/3 | 1,227 | (hmxaqjqdnw) = zzrhesjkqm fvfkachgsq (setdfpzidl ) | Positive | 23 Nov 2023 | ||
Placebo | (hmxaqjqdnw) = amqgswxscw fvfkachgsq (setdfpzidl ) |